Dr. Benjamin A. Weinberg
Claim this profileMedStar Georgetown University Hospital
Studies Colorectal Cancer
Studies Adenocarcinoma
17 reported clinical trials
35 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
KRAS negative
NRAS negative
2Adenocarcinoma
Stage IV
KRAS negative
NRAS negative
Affiliated Hospitals
Clinical Trials Benjamin A. Weinberg is currently running
Anti-CD38 + KRAS Vaccine + Anti-PD-1
for Pancreatic & Lung Cancer
The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * How well does daratumumab and nivolumab, when given with a vaccine, control or stop these types of cancer? * How well does participants bodies handle these study drugs? * Does this combination of study drugs help participants live longer? Participants will receive daratumumab, nivolumab with KRAS vaccine and have regular tests and procedures to follow how the participants are doing on these study drugs.
Recruiting1 award Phase 213 criteria
Proglumide + Chemotherapy
for Pancreatic Cancer
This is a Phase 2 study with an open labelled lead-in study to approximately treat 30 patients \[6 subjects for Lead-in and 24 for Phase 2\] enrolled with metastatic pancreatic cancer with combination therapy using standard of care first line therapy with GEM-NAB-P (GEM 1000mg/m2 IV and NAB-P 125 mg/m2 given days 1, 8, and 15 every 28 days, and proglumide will be tested at the daily dose of 1200 mg orally given as 400 mg po TID. The lead-in study will determine the safety and tolerability of the 1200 mg daily dose of proglumide with standard of care GEM-NAB-P. If 0 or 1 of a total of 6 patients at 400mg experiences a DLT, then we will proceed to the Phase 2 randomized trial.
Recruiting0 awards Phase 29 criteria
More about Benjamin A. Weinberg
Clinical Trial Related1 year of experience running clinical trials · Led 17 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Benjamin A. Weinberg has experience with
- Nivolumab
- Panitumumab
- Regorafenib
- SM08502
- MFOLFIRINOX
- Daratumumab
Breakdown of trials Benjamin A. Weinberg has run
Colorectal Cancer
Adenocarcinoma
Pancreatic Cancer
Colon Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Benjamin A. Weinberg specialize in?
Benjamin A. Weinberg focuses on Colorectal Cancer and Adenocarcinoma. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are KRAS negative.
Is Benjamin A. Weinberg currently recruiting for clinical trials?
Yes, Benjamin A. Weinberg is currently recruiting for 8 clinical trials in Washington District of Columbia. If you're interested in participating, you should apply.
Are there any treatments that Benjamin A. Weinberg has studied deeply?
Yes, Benjamin A. Weinberg has studied treatments such as Nivolumab, Panitumumab, Regorafenib.
What is the best way to schedule an appointment with Benjamin A. Weinberg?
Apply for one of the trials that Benjamin A. Weinberg is conducting.
What is the office address of Benjamin A. Weinberg?
The office of Benjamin A. Weinberg is located at: MedStar Georgetown University Hospital, Washington, District of Columbia 20007 United States. This is the address for their practice at the MedStar Georgetown University Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.